These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


315 related items for PubMed ID: 23082595

  • 1. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
    Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [Abstract] [Full Text] [Related]

  • 3. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [Abstract] [Full Text] [Related]

  • 4. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine.
    Madhi SA, Cutland C, Jones S, Groome M, Ortiz E.
    S Afr Med J; 2011 Nov 28; 101(12):879-83. PubMed ID: 22273029
    [Abstract] [Full Text] [Related]

  • 5. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2012 Jan 28; 31(1):e24-30. PubMed ID: 22157567
    [Abstract] [Full Text] [Related]

  • 6. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
    Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 May 28; 43(3):687-98. PubMed ID: 23077849
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine.
    Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E.
    Indian Pediatr; 2009 Nov 28; 46(11):975-82. PubMed ID: 19955579
    [Abstract] [Full Text] [Related]

  • 8. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.
    Vaccine; 2011 Nov 21; 29(50):9337-44. PubMed ID: 22001281
    [Abstract] [Full Text] [Related]

  • 9. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L.
    Vaccine; 2007 Jan 22; 25(6):1055-63. PubMed ID: 17049692
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ.
    Vaccine; 2006 May 29; 24(22):4727-36. PubMed ID: 16616973
    [Abstract] [Full Text] [Related]

  • 11. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
    Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E.
    Vaccine; 2012 Oct 05; 30(45):6492-500. PubMed ID: 22863658
    [Abstract] [Full Text] [Related]

  • 12. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, Elrick DB, Jacquet JM.
    Vaccine; 2006 May 01; 24(18):4017-23. PubMed ID: 16516357
    [Abstract] [Full Text] [Related]

  • 13. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L.
    Pediatr Infect Dis J; 2006 Aug 01; 25(8):706-12. PubMed ID: 16874170
    [Abstract] [Full Text] [Related]

  • 14. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY, Wang YH, Chang LY, Huang YC, Kao HT, Lin PY, Lu HK, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Mar 01; 11(2):129-36. PubMed ID: 16762579
    [Abstract] [Full Text] [Related]

  • 15. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Torres V.
    Pediatrics; 2007 Jan 01; 119(1):e179-85. PubMed ID: 17145903
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand.
    Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2010 Mar 01; 41(2):450-62. PubMed ID: 20578530
    [Abstract] [Full Text] [Related]

  • 17. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM.
    Pediatr Infect Dis J; 1998 Apr 01; 17(4):294-304. PubMed ID: 9576383
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 01; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 19. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O.
    Hum Vaccin Immunother; 2014 Aug 01; 10(10):2795-8. PubMed ID: 25483640
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH.
    Vaccine; 2011 Feb 11; 29(8):1551-7. PubMed ID: 21215828
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.